UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

The New England journal of medicine, 2018-09, Vol.379 (11), p.1017-1027

2018

Volltextzugriff (PDF)

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1075-1084

2016

Volltextzugriff (PDF)

Longitudinal changes in self-reported walking ability in multiple sclerosis

PloS one, 2015-05, Vol.10 (5), p.e0125002-e0125002

2015

Volltextzugriff (PDF)

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials

Multiple sclerosis journal - experimental, translational and clinical, 2018-04, Vol.4 (2), p.2055217318778610-2055217318778610

2018

Volltextzugriff (PDF)

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

Therapeutic Advances in Neurological Disorders, 2011-09, Vol.4 (5), p.281-296

2011

Volltextzugriff (PDF)

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo

Multiple sclerosis journal - experimental, translational and clinical, 2017-09, Vol.3 (3), p.2055217317730096-2055217317730096

2017

Volltextzugriff (PDF)

Corpus callosum index and long-term disability in multiple sclerosis patients

Journal of neurology, 2010-08, Vol.257 (8), p.1256-1264

2010

Volltextzugriff (PDF)

Headache in Multiple Sclerosis

Current pain and headache reports, 2010-08, Vol.14 (4), p.316-320

2010

Volltextzugriff (PDF)

Kinesthesia is impaired in focal dystonia

Movement disorders, 2006-06, Vol.21 (6), p.754-760

2006

Volltextzugriff (PDF)

Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS

Neurology, 2013-04, Vol.80 (16), p.1509

2013

Volltextzugriff (PDF)

Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation

JAMA neurology, 2016-11, Vol.73 (11), p.1375

2016

Volltextzugriff (PDF)

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

JAMA neurology, 2015-01, Vol.72 (1), p.31

2015

Volltextzugriff (PDF)

Review: Natalizumab in the treatment of multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2009-03, Vol.2 (2), p.115-128

2009

Volltextzugriff (PDF)

Fatigue and progression of corpus callosum atrophy in multiple sclerosis

Journal of neurology, 2011-12, Vol.258 (12), p.2199-2205

2011

Volltextzugriff (PDF)

Effects of Natalizumab on Circulating B Cells, T Regulatory Cells and Natural Killer Cells

European neurology, 2010-05, Vol.63 (5), p.311-317

2010

Volltextzugriff (PDF)

Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

European neurology, 2011-04, Vol.65 (4), p.231-232

2011

Volltextzugriff (PDF)

Multiple sclerosis associated fatigue during natalizumab treatment

Journal of the neurological sciences, 2009-10, Vol.285 (1), p.109-113

2009

Volltextzugriff (PDF)

CD4 +CD25 +FoxP3 + T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis

Journal of neuroimmunology, 2006-11, Vol.180 (1), p.178-184

2006

Volltextzugriff (PDF)

Vitamin D levels in Swiss multiple sclerosis patients

Swiss medical weekly, 2011, Vol.141, p.w13192

2011

Volltextzugriff (PDF)

Natalizumab in the treatment of multiple sclerosis

Therapeutic advances in neurological disorders, 2009-03, Vol.2 (2), p.115-128

2009

Volltextzugriff (PDF)

Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland

European neurology, 2010-02, Vol.63 (2), p.101-106

2010

Volltextzugriff (PDF)

Natalizumab and Beyond

European neurology, 2010-10, Vol.64 (4), p.236-240

2010

Volltextzugriff (PDF)

Prevalence and Severity of Multiple-Sclerosis-Associated Fatigue in Treated and Untreated Patients

European neurology, 2008-02, Vol.59 (3-4), p.136-142

2008

Volltextzugriff (PDF)

Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation

European journal of neurology, 2010-11, Vol.17 (11), p.e105-e105

2010

Volltextzugriff (PDF)

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

Journal of neurology, 2007-01, Vol.254 (1), p.67-77

2007

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(38)
Berichte
(2)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Humans
(28)
Neurosciences & Neurology
(24)
Clinical Neurology
(23)
Multiple Sclerosis
(23)
Female
(22)
Male
(22)
Adult
(20)
Neurosciences
(17)
Middle Aged
(14)
Neurology
(9)
Natalizumab
(8)
Adolescent
(7)
Biological And Medical Sciences
(7)
Magnetic Resonance Imaging
(7)
Medical Sciences
(7)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(7)
Antibodies, Monoclonal, Humanized
(6)
Original Paper
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Longitudinal changes in self-reported walking ability in multiple sclerosis

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo

Corpus callosum index and long-term disability in multiple sclerosis patients

Headache in Multiple Sclerosis

Kinesthesia is impaired in focal dystonia

Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS

Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

Review: Natalizumab in the treatment of multiple sclerosis

Fatigue and progression of corpus callosum atrophy in multiple sclerosis

Effects of Natalizumab on Circulating B Cells, T Regulatory Cells and Natural Killer Cells

Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

Multiple sclerosis associated fatigue during natalizumab treatment

CD4 +CD25 +FoxP3 + T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis

Vitamin D levels in Swiss multiple sclerosis patients

Natalizumab in the treatment of multiple sclerosis

Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland

Natalizumab and Beyond

Prevalence and Severity of Multiple-Sclerosis-Associated Fatigue in Treated and Untreated Patients

Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

Suchergebnisse filtern